RicercaInizia una nuova ricerca
NOTA: è possibile cercare una corrispondenza esatta usando i doppi apici, ad es: "evoluzione della specie". Qualora si cerchi un identificativo, è consigliabile cercarlo in due modi differenti: tra apici con caratteri speciali es: "978-94-6366-274" oppure senza caratteri speciali solo come sequenza numerica: es 978946366274.
. The level of HER2/neu amplification may have a correlation with some relevant histopathologcal features of early stage breast cancer
2006-01-01 Gullo, G; Bettio, D; Masci, G; Torri, V; Di Tommaso, L; Banna, G; Santoro, A
A. Micrometastasis in sentinel (SLN) and non sentinel lymph nodes of breast cancer: an update including clinico-pathologic impact and survaival
2006-01-01 Masci, G; Di Tommaso, L; Del Prato, I; Orefice, S; Rubino, A; Morenghi, E; Salvini, P; Alloisio, M; Morenghi, E; Roncalli, M; Santoro, A
A. Micrometastasis in sentinel (SLN) and non sentinel lymph nodes of breast cancer: an update including clinico-pathologic impact and survaival
2005-01-01 Masci, G; Di Tommaso, L; Del Prato, I; Orefice, S; Rubino, A; Morenghi, E; Salvini, P; Alloisio, M; Morenghi, E; Roncalli, M; Santoro, A.
Can We Predict the Benefit of the 70-Gene Signature in the Choice of Adjuvant Systemic Treatment for ER Positive, HER2 Negative Tumors in Daily Practice? A Single Institution Experience
2011-01-01 Torrisi, R; Garcia-Etienne, Ca; Losurdo, A; Morenghi, E; Di Tommaso, L; Gatzemeier, W; Sagona, A; Rossetti, C; Eboli, M; Rubino, A; Barbieri, E; Andreoli, C; Orefice, S; Gandini, C; Masci, G; Santoro, A; Tinterri, C
Characterization of a young women population affected with breast cancer and tested for BRCA1/BRCA2 gene mutations: a monocentric series
2012-01-01 Zuradelli, M; Ripamonti, Cb; Torrisi, R; Basilico, V; Tinterri, C; Testori, A; Di Tommaso, L; Bernard, L; Radice, P; Santoro, A
Imatinib mesylate in desmoplastic small round cell tumour
2012-01-01 Bertuzzi, A; Bisogno, G; Carli, M; Ferrari, A; Comandone, A; Gasco, M; De Sanctis, R; Gnocchi, C; Santoro, A
Neutrophil to Lymphocyte Ratio (NLR) as predictive factor in patients with metastatic soft tissue sarcoma (STS) treated with trabectedin (T).
2013-01-01 De Sanctis, R; Quagliuolo, V; Viganò, A; Lutman, Fr; Bertuzzi, Af; Marchetti, S; Zucali, Pa; Santoro, A
Phase I, pharmacokinetics, pharmacodynamic study of lapatinib in combination with sorafenib in patients with advanced refractory solid tumors
2011-01-01 Simonelli, M; Zucali, Pa; De Sanctis, R; Lorenzi, E; De Vincenzo, F; Rimassa, L; Tronconi, Mc; Personeni, N; Masci, G; Zuradelli, M; Giordano, L; Santoro, A
Superiority of CHOI vs RECIST criteria in evaluating outcome of advanced soft tissue sarcoma (STS) patients treated with sorafenib
2012-01-01 De Sanctis, R; Bertuzzi, A; Magnoni, P; Giordano, L; Gasco, M; Lutman, R; Santoro, A
“La localizzazione anatomica delle micrometastasi di carcinoma mammario al linfonodo sentinella e’ predittiva dello stato della dissezione ascellare”
2005-01-01 Di Tommaso, L; Arizzi, C; Rahal, D; Destro, A; Alloisio, M; Orefice, S; Rubino, A; Morenghi, E; Masci, G; Del Prato, I; Sacco, R; Santoro, A; Roncalli, M
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| . The level of HER2/neu amplification may have a correlation with some relevant histopathologcal features of early stage breast cancer | 1-gen-2006 | Gullo, G; Bettio, D; Masci, G; Torri, V; Di Tommaso, L; Banna, G; Santoro, A | |
| A. Micrometastasis in sentinel (SLN) and non sentinel lymph nodes of breast cancer: an update including clinico-pathologic impact and survaival | 1-gen-2006 | Masci, G; Di Tommaso, L; Del Prato, I; Orefice, S; Rubino, A; Morenghi, E; Salvini, P; Alloisio, M; Morenghi, E; Roncalli, M; Santoro, A | |
| A. Micrometastasis in sentinel (SLN) and non sentinel lymph nodes of breast cancer: an update including clinico-pathologic impact and survaival | 1-gen-2005 | Masci, G; Di Tommaso, L; Del Prato, I; Orefice, S; Rubino, A; Morenghi, E; Salvini, P; Alloisio, M; Morenghi, E; Roncalli, M; Santoro, A. | |
| Can We Predict the Benefit of the 70-Gene Signature in the Choice of Adjuvant Systemic Treatment for ER Positive, HER2 Negative Tumors in Daily Practice? A Single Institution Experience | 1-gen-2011 | Torrisi, R; Garcia-Etienne, Ca; Losurdo, A; Morenghi, E; Di Tommaso, L; Gatzemeier, W; Sagona, A; Rossetti, C; Eboli, M; Rubino, A; Barbieri, E; Andreoli, C; Orefice, S; Gandini, C; Masci, G; Santoro, A; Tinterri, C | |
| Characterization of a young women population affected with breast cancer and tested for BRCA1/BRCA2 gene mutations: a monocentric series | 1-gen-2012 | Zuradelli, M; Ripamonti, Cb; Torrisi, R; Basilico, V; Tinterri, C; Testori, A; Di Tommaso, L; Bernard, L; Radice, P; Santoro, A | |
| Imatinib mesylate in desmoplastic small round cell tumour | 1-gen-2012 | Bertuzzi, A; Bisogno, G; Carli, M; Ferrari, A; Comandone, A; Gasco, M; De Sanctis, R; Gnocchi, C; Santoro, A | |
| Neutrophil to Lymphocyte Ratio (NLR) as predictive factor in patients with metastatic soft tissue sarcoma (STS) treated with trabectedin (T). | 1-gen-2013 | De Sanctis, R; Quagliuolo, V; Viganò, A; Lutman, Fr; Bertuzzi, Af; Marchetti, S; Zucali, Pa; Santoro, A | |
| Phase I, pharmacokinetics, pharmacodynamic study of lapatinib in combination with sorafenib in patients with advanced refractory solid tumors | 1-gen-2011 | Simonelli, M; Zucali, Pa; De Sanctis, R; Lorenzi, E; De Vincenzo, F; Rimassa, L; Tronconi, Mc; Personeni, N; Masci, G; Zuradelli, M; Giordano, L; Santoro, A | |
| Superiority of CHOI vs RECIST criteria in evaluating outcome of advanced soft tissue sarcoma (STS) patients treated with sorafenib | 1-gen-2012 | De Sanctis, R; Bertuzzi, A; Magnoni, P; Giordano, L; Gasco, M; Lutman, R; Santoro, A | |
| “La localizzazione anatomica delle micrometastasi di carcinoma mammario al linfonodo sentinella e’ predittiva dello stato della dissezione ascellare” | 1-gen-2005 | Di Tommaso, L; Arizzi, C; Rahal, D; Destro, A; Alloisio, M; Orefice, S; Rubino, A; Morenghi, E; Masci, G; Del Prato, I; Sacco, R; Santoro, A; Roncalli, M |
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile
Opzioni
Scopri
Tipologia
- 4 Contributo in Atti di Convegno ... 10
- 4 Contributo in Atti di Convegno ... 10
Data di pubblicazione
- 2013 1
- 2012 3
- 2011 2
- 2006 2
- 2005 2
Rivista
- ANNALS OF ONCOLOGY 4
- JOURNAL OF CLINICAL ONCOLOGY 2
- CANCER RESEARCH 1
- EUROPEAN JOURNAL OF CANCER. SUPPL... 1
- PATHOLOGICA 1
- THE BREAST 1
Lingua
- eng 3
- ita 1
Accesso al fulltext
- no fulltext 10